ARO-ENaC ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 299 | 嚢胞性線維症 | 1 |
299. 嚢胞性線維症
臨床試験数 : 1,696 / 薬物数 : 1,644 - (DrugBank : 272) / 標的遺伝子数 : 96 - 標的パスウェイ数 : 170
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04375514 (ClinicalTrials.gov) | August 10, 2020 | 30/4/2020 | Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis | A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability and Pharmacokinetic Effects of ARO-ENaC in Normal Healthy Volunteers and Safety, Tolerability and Efficacy in Patients With Cystic Fibrosis | Cystic Fibrosis, Pulmonary | Drug: ARO-ENaC;Drug: Placebo | Arrowhead Pharmaceuticals | NULL | Recruiting | 18 Years | 55 Years | All | 92 | Phase 1/Phase 2 | Australia;New Zealand |